<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03324477</url>
  </required_header>
  <id_info>
    <org_study_id>11-2017</org_study_id>
    <nct_id>NCT03324477</nct_id>
  </id_info>
  <brief_title>Hypertonic Saline Preload Versus Coload in TURP Surgery</brief_title>
  <official_title>The Hemodynamic Effects of Hypertonic Saline Preload Versus Coload Measured by Non-invasive Cardiometry in Patients Undergoing TURP Surgery: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the relevance of the timing of hypertonic saline
      administration either as a preload or as a coload on hemodynamic parameters in patients
      undergoing TURP surgeries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Benign prostatic hyperplasia is common in elderly males, and this group of patients is
      commonly associated with different comorbidities especially of the cardiovascular system ,
      this make them at risk of many intraoperative complications. The associated adverse effects
      arising in both the cardiovascular and nervous systems are known as transurethral resection
      (TUR) syndrome.Therefore TURP patients need meticulous monitoring of hemodynamics and fluid
      therapy.

      This study is designed to investigate the relevance of the timing of hypertonic saline
      administration either as a preload or as a coload on hemodynamic parameters in patients
      undergoing TURP surgeries.

      100 ASA physical status I-III male patients scheduled to electively undergo transurethral
      resection of the prostate under spinal subarachnoid block were included in this study

      Preload group (Group P):

      50 Patients will receive 4 ml/kg of hypertonic saline (NaCL3%) via G14 cannula over 15-20 min
      before the induction of spinal anaesthesia.

      Co-load group (Group C):

      50 Patients will receive 4 ml/kg of hypertonic saline (NaCL3%) via G14 cannula at the maximal
      possible rate at the time of identification of C.S.F .
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>systolic blood pressure</measure>
    <time_frame>two hours</time_frame>
    <description>systolic blood pressure is measured by mmHg</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Transurethral Resection of Prostate Syndrome</condition>
  <arm_group>
    <arm_group_label>preload group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 4 ml/kg of hypertonic saline 3% via G14 cannula over 15-20 min before the induction of spinal anaesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>coload group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 4 ml/kg of hypertonic saline 3% via G14cannula at the maximal possible rate at the time of identification of C.S.F .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hypertonic saline 3%</intervention_name>
    <description>hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma</description>
    <arm_group_label>preload group</arm_group_label>
    <arm_group_label>coload group</arm_group_label>
    <other_name>hypertonic saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) physical status I - III.

        Exclusion Criteria:

          -  Patient refusal.

          -  Patient in whom spinal anesthesia is absolutely contraindicated.

          -  Known sensitivity to local anesthetics.

          -  Preoperative electrolyte imbalance.

          -  Preoperative uncontrolled hypertension or congestive heart failure.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manar M Elkholy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manal M Elgohary, MD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of medicine Cairo niversity</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nazmy E Seif, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shaimaa A Wahba, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of medicine , Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2017</study_first_submitted>
  <study_first_submitted_qc>October 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Shaimaa Ahmed Abdelghany Wahba</investigator_full_name>
    <investigator_title>Clinical Demonstrator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

